<DOC>
	<DOCNO>NCT01411657</DOCNO>
	<brief_summary>Ciliary Neurotrophic Factor ( CNTF ) demonstrate multiple preclinical model enhance survival regeneration retinal ganglion cell , retinal neuron injured disease like ischemic optic neuropathy/optic nerve stroke . We hypothesize CNTF delivery human eye provide neuroprotection ( prevent loss vision ) neuroenhancement ( improve vision index ) ischemic optic neuropathy . Patients trial receive NT-501 CNTF implant ( make Neurotech ) one eye , carefully follow evaluate safety efficacy .</brief_summary>
	<brief_title>NT-501 CNTF Implant Ischemic Optic Neuropathy : Safety , Neuroprotection Neuroenhancement</brief_title>
	<detailed_description />
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Optic Nerve Diseases</mesh_term>
	<mesh_term>Optic Neuropathy , Ischemic</mesh_term>
	<criteria>age 40 year old must understand sign informed consent must medically able undergo ophthalmic surgery NT501 device insertion possible removal , well test require . diagnosis ischemic optic neuropathy characterize ( ) nonarteritic subtype , include normal ESR CRP ; ( b ) syndrome acute unilateral visual loss document optic nerve head edema without significant pain ; ( c ) relative afferent papillary defect affect eye , decrease bestcorrected visual acuity 20/40 worse affect eye , detectable loss visual field test consistent nerve fiber visual field defect retain measurable residual visual field preservation . corneal , lens , optic nerve retinal disease cause vision loss , blind one eye requirement acyclovir and/or relate product study receive systemic steroid immunosuppressive medication . pregnant lactating . consider immunodeficient know history human immunodeficiency virus ( HIV ) chemotherapy , history malignancy , UNLESS treat successfully 2 year prior inclusion trial .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>